Collegium's $155M Pain Cash Flow Is Fueling a Bigger ADHD Story

Pain Is Now the Cash Engine Behind Collegium's ADHD Push

The key shift is simple: Collegium's pain business is no longer the whole story. It is the cash engine. In the first quarter, the pain portfolio produced $154.6 million, while total revenue reached $193.5 million, up 9% year over year. For now, that mature business is funding the next growth curve rather than asking the market to underwrite it on faith alone.

JORNAY PM is making the ADHD story easier to underwrite

On the ADHD side, the momentum is still clear. JORNAY PM generated $38.9 million in quarterly revenue, up 36% year over year, and prescriptions rose 14%, reflecting gains in new prescribers and market share. That makes the franchise look less like a short-lived launch and more like an extending growth leg.

AZSTARYS adds the next milestone. Collegium says it is on track to close the acquisition in the second quarter of 2026, which would add a complementary ADHD medicine and extend revenue into the late 2030s. Management has also said the deal is expected to be immediately accretive to adjusted EBITDA, giving investors a reason to start thinking about Collegium as a broader ADHD platform.

Pain is still keeping the lights on. ADHD is where a higher multiple could come from if execution holds.

Why the AZSTARYS Deal Makes Business Sense

Collegium is using a steady cash generator to buy a larger, longer-lasting piece of the business.

Funding and commercial proof

At first glance, paying $650 million upfront for AZSTARYS looks like a meaningful commitment. Collegium ended the first quarter with $421.8 million in cash, cash equivalents, and marketable securities, and management expects leverage of about 2x at closing when the deal funding is factored in. In other words, this looks more like a balance-sheet-supported acquisition than a fully desperate stretch.

The commercial rationale is also tangible. AZSTARYS logged more than 760,000 prescriptions in 2025, is supported by six Orange Book patents mostly expiring in December 2037, and is expected to produce more than $50 million of net revenue in the second half of 2026.

The re-rating case depends on platform breadth, not just growth

The bullish case is not only that Collegium is growing. It is that the company could be valued differently. The legacy 2026 outlook is steady rather than explosive: $805 million to $825 million in revenue and $455 million to $475 million in adjusted EBITDA. Jornay PM, by contrast, is still guided for strong growth at $190 million to $200 million.

If AZSTARYS closes and integrates smoothly, investors may start underwriting a broader ADHD platform rather than a single fast-growing product backed by a mature cash cow.

What skeptics will watch

Skeptics are likely to focus on debt, integration execution, and the fact that management expects modest pressure in the pain portfolio as Nucynta faces generic competition. Those are fair concerns.

Key signals to watch over the next few quarters:

• Close timing: whether AZSTARYS closes when expected in the second quarter of 2026.
• Integration pace: management plans to expand the ADHD sales force from 125 to 180 representatives.
• Leverage: whether debt stays close to the expected about 2x at closing.
• Commercial traction: whether AZSTARYS continues to support the expectation of more than $50 million of second-half 2026 revenue.

If those markers hold, the pain business does more than fund operations. It underwrites the next stage of the company.

What Would Confirm the ADHD Re-Rating

A higher multiple can look plausible on paper, but it only holds if execution keeps delivering fresh proof.

Confirmation signals

The cleanest confirmation is a timely AZSTARYS closing in the second quarter of 2026. That would be the first real step toward treating Collegium as an ADHD platform rather than a company merely discussing one.

After closing, the next important check is whether AZSTARYS stays on track to deliver more than $50 million of net revenue in H2 2026 and remains immediately accretive to adjusted EBITDA. If that happens, investors have a reason to pay for near-term cash contribution as well as a longer patent tail.

JORNAY PM also needs to keep performing. Management reported net revenue up 36% and prescriptions up 14% in the first quarter, and another strong quarter after the acquisition would help show that the expanded ADHD sales force is adding value.

None of this requires the pain business to grow quickly. It just needs to remain a dependable funder.

When the story gets harder to defend

The valuation case works best when investors treat ADHD as the growth engine and pain as the funding source. That setup becomes much harder to defend if pain weakens before ADHD proves it can carry more weight.

The bear case does not require AZSTARYS to fail. It only requires the financing and execution logic to break down: delayed closing, slower-than-expected commercial uptake, rising leverage without matching cash flow, or a meaningful slowdown in the pain portfolio before the ADHD platform can expand. If those pressures stack up, the story stops looking like a re-rating and starts looking like a mature franchise paying too much for a patch.